| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 7,367 | 6,733 | 6,457 | 6,073 |
| Product | 3,842 | 3,150 | - | - |
| Product And Service Other | 155 | 106 | - | - |
| Total cost of revenue | 3,997 | 3,256 | 3,519 | 14,519 |
| Research and development | 2,844 | 2,931 | 2,370 | 4,717 |
| Selling, general and administrative | 9,064 | 8,346 | 9,033 | 9,464 |
| Intangible assets and other long-lived assets impairment | 0 | 0 | - | 19,504 |
| Restructuring costs | 0 | 0 | - | 1,770 |
| Total operating expenses | 11,908 | 11,277 | 11,403 | 35,455 |
| Loss from operations | -8,538 | -7,800 | -8,465 | -43,901 |
| Interest income | 268 | 277 | 290 | 376 |
| Other income (expense) | -219 | 676 | 5,080 | -697 |
| Total other income (expense) | 49 | 953 | 5,370 | -321 |
| Loss before income taxes | -8,489 | -6,847 | -3,095 | -44,222 |
| Provision for income taxes | 14 | 10 | 7 | 24 |
| Net loss | -8,503 | -6,857 | -3,102 | -44,246 |
| Net loss per share, basic (in dollars per share) | -1.59 | -1.99 | -1.15 | -0.52 |
| Net loss per share, diluted (in dollars per share) | -1.59 | -1.99 | -1.15 | -0.52 |
| Weighted-average common shares outstanding, basic (in shares) | 5,338,000 | 3,441,000 | 2,694,000 | 85,870,000 |
| Weighted-average common shares outstanding, diluted (in shares) | 5,338,000 | 3,441,000 | 2,694,000 | 85,870,000 |
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)